CD274 and neoplasm: Furthermore, anti-PD-1/PD-L1 antibodies in combination with DC-based vaccines have been extensively explored in a variety of murine tumor models (158–164) and, without exception, combination treatment has shown superior efficacy compared to monotherapy, with stronger anti-tumor-specific T-cell responses and lower immunosuppressive cell infiltration.